US 12,139,524 B2
Immune cell compositions and methods of use
Prasad S. Adusumilli, New York, NY (US); and Michel Sadelain, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Dec. 21, 2021, as Appl. No. 17/557,607.
Application 17/557,607 is a division of application No. 15/757,276, granted, now 11,242,375, previously published as PCT/US2016/050128, filed on Sep. 2, 2016.
Claims priority of provisional application 62/214,809, filed on Sep. 4, 2015.
Prior Publication US 2022/0112263 A1, Apr. 14, 2022
Int. Cl. A61K 35/17 (2015.01); A61K 35/28 (2015.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/48 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 9/64 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); A61K 35/28 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 38/193 (2013.01); A61K 38/2013 (2013.01); A61K 38/4873 (2013.01); A61K 39/0011 (2013.01); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001114 (2018.08); A61K 39/001119 (2018.08); A61K 39/001122 (2018.08); A61K 39/001124 (2018.08); A61K 39/001126 (2018.08); A61K 39/001128 (2018.08); A61K 39/001129 (2018.08); A61K 39/001153 (2018.08); A61K 39/001157 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/00117 (2018.08); A61K 39/001171 (2018.08); A61K 39/001174 (2018.08); A61K 39/00118 (2018.08); A61K 39/001182 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001195 (2018.08); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 14/70503 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 9/6472 (2013.01); C12Y 304/22062 (2013.01); A61K 38/00 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/00 (2013.01)] 18 Claims
 
1. A polypeptide that is a dominant negative form of programmed death 1 (PD-1), wherein the dominant negative form (a) lacks a signaling domain, (b) comprises a CD8 transmembrane domain, and (c) comprises an extracellular domain comprising the ligand binding domain of PD-1, wherein the extracellular domain is fused to the CD8 transmembrane domain, and wherein the dominant negative form comprises amino acids 21-244 of SEQ ID NO: 43.